Abstract
Background: Biomarkers for the diagnostic classification of pancreatic cysts are urgently needed. Deregulated microRNA (miRNAs) expression is widespread in pancreatic cancer. We assessed whether aberrant miRNAs in pancreatic cyst fluid could be used as potential biomarkers for cystic precursor lesions of pancreatic cancer. Methods: Cyst fluid specimens were prospectively collected from 40 surgically resected pancreatic cysts, and small RNAs were extracted. The ‘mucinous’ cohort included 14 intraductal papillary mucinous neoplasms (including 3 with an associated adenocarcinoma) and 10 mucinous cystic neoplasms; the ‘nonmucinous’ cohort included 11 serous cystadenomas and 5 other benign cysts. Quantitative reverse transcription PCR was performed for five miRNAs (miR-21, miR-155, miR-221, miR-17-3p, miR-191), which were previously reported as overexpressed in pancreatic adenocarcinomas. Results: Significantly higher expression of miR-21, miR-221, and miR-17-3p was observed in the mucinous versus nonmucinous cysts (p < 0.01), with the mean relative fold differences being 7.0-, 7.9-, and 5.4-fold, respectively. Receiver operating characteristic curves demonstrated the highest median area under the curve for miR-21, with a median specificity of 76%, at a sensitivity of 80%. Conclusion: This pilot study demonstrates that profiling miRNAs in pancreatic cyst fluid samples is feasible and can yield potential biomarkers for the classification of cystic lesions of the pancreas.
References
1.
Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.
2.
Maitra A, Hruban RH: Pancreatic cancer. Annu Rev Pathol 2008;3:157–188.
3.
Yachida S, Jones S, Bozic I, et al: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114–1117.
4.
Maitra A, Fukushima N, Takaori K, Hruban RH: Precursors to invasive pancreatic cancer. Adv Anat Pathol Mar 2005;12:81–91.
5.
Hruban RH, Adsay NV, Albores-Saavedra J, et al: Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001;25:579–586.
6.
Singh M, Maitra A: Precursor lesions of pancreatic cancer: molecular pathology and clinical implications. Pancreatology 2007;7:9–19.
7.
Adsay NV: Cystic neoplasia of the pancreas: pathology and biology. J Gastrointest Surg 2008;12:401–404.
8.
Basturk O, Coban I, Adsay NV: Pancreatic cysts: pathologic classification, differential diagnosis, and clinical implications. Arch Pathol Lab Med 2009;133:423–438.
9.
Garcea G, Ong SL, Rajesh A, et al: Cystic lesions of the pancreas. A diagnostic and management dilemma. Pancreatology 2008;8:236–251.
10.
Di Magno EP: The pancreatic cyst incidentaloma: management consensus? Clin Gastroenterol Hepatol 2007;5:797–798.
11.
Fernandez-del Castillo C, Targarona J, Thayer SP, Rattner DW, Brugge WR, Warshaw AL: Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg 2003;138:427–423.
12.
Kiely JM, Nakeeb A, Komorowski RA, Wilson SD, Pitt HA: Cystic pancreatic neoplasms: enucleate or resect? J Gastrointest Surg 2003;7:890–897.
13.
Winter JM, Cameron JL, Lillemoe KD, et al: Periampullary and pancreatic incidentaloma: a single institution’s experience with an increasingly common diagnosis. Ann Surg 2006;243:673–680.
14.
Tanaka M, Chari S, Adsay V, et al: International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006;6:17–32.
15.
Ferrone CR, Correa-Gallego C, Warshaw AL, et al: Current trends in pancreatic cystic neoplasms. Arch Surg 2009;144:448–454.
16.
Khalid A, Brugge W: ACG practice guidelines for the diagnosis and management of neoplastic pancreatic cysts. Am J Gastroenterol 2007;102:2339–2349.
17.
Hutchins G, Draganov PV: Diagnostic evaluation of pancreatic cystic malignancies. Surg Clin North Am 2010;90:399–410.
18.
Scheiman JM: Management of cystic lesions of the pancreas. J Gastrointest Surg 2008;12:405–407.
19.
Visser BC, Muthusamay VR, Mulvihill SJ, Coakley F: Diagnostic imaging of cystic pancreatic neoplasms. Surg Oncol 2004;13:27–39.
20.
Ryu JK, Woo SM, Hwang JH, et al: Cyst fluid analysis for the differential diagnosis of pancreatic cysts. Diagn Cytopathol 2004;31:100–105.
21.
Frossard JL, Amouyal P, Amouyal G, et al: Performance of endosonography-guided fine needle aspiration and biopsy in the diagnosis of pancreatic cystic lesions. Am J Gastroenterol 2003;98:1516–1524.
22.
Pitman MB, Lewandrowski K, Shen J, Sahani D, Brugge W, Fernandez-del Castillo C: Pancreatic cysts: preoperative diagnosis and clinical management. Cancer Cytopathol 2010;118:1–13.
23.
Bartels CL, Tsongalis GJ: MicroRNAs: novel biomarkers for human cancer. Clin Chem 2009;55:623–631.
24.
Croce CM, Calin GA: miRNAs, cancer, and stem cell division. Cell 2005;122:6–7.
25.
Szafranska AE, Davison TS, John J, et al: MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007;26:4442–4452.
26.
Lee EJ, Gusev Y, Jiang J, et al: Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007;120:1046–1054.
27.
Bloomston M, Frankel WL, Petrocca F, et al: MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007;297:1901–1908.
28.
Kent OA, Mullendore M, Wentzel EA, et al: A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther 2009;8:2013–2024.
29.
Habbe N, Koorstra JB, Mendell JT, et al: MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther 2009;8:340–346.
30.
Ryu JK, Hong SM, Karikari CA, Hruban RH, Goggins MG, Maitra A: Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology 2010;10:66–73.
31.
du Rieu MC, Torrisani J, Selves J, et al: MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem 2010;56:603–612.
32.
Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513–10518.
33.
Li A, Omura N, Hong SM, et al: Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res 2010;70:5226–5237.
34.
Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X: Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010;127:118–126.
35.
Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B: Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 2009;4:e6229.
36.
Hruban RH, Klimstra DS, Pitman MB: Tumors of the Pancreas. Washington, American Registry of Pathology, 2006.
37.
Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3:1101–1108.
38.
Brugge WR: Role of endoscopic ultrasound in the diagnosis of cystic lesions of the pancreas. Pancreatology 2001;1:637–640.
39.
Das A, Ngamruengphong S, Nagendra S, Chak A: Asymptomatic pancreatic cystic neoplasm: a cost-effectiveness analysis of different strategies of management. Gastrointest Endosc 2009;70:690–699.
40.
Canto MI: Strategies for screening for pancreatic adenocarcinoma in high-risk patients. Semin Oncol 2007;34:295–302.
41.
Thosani N, Thosani S, Qiao W, Fleming JB, Bhutani MS, Guha S: Role of EUS-FNA-based cytology in the diagnosis of mucinous pancreatic cystic lesions: a systematic review and meta-analysis. Dig Dis Sci 2010;55:2756–2766.
42.
Brugge WR, Lewandrowski K, Lee-Lewandrowski E, et al: Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology 2004;126:1330–1336.
43.
Pitman MB, Lewandrowski K, Shen J, Sahani D, Brugge W, Fernandez-del Castillo C: Pancreatic cysts: preoperative diagnosis and clinical management. Cancer Cytopathol 2010;118:1–13.
44.
van der Waaij LA, van Dullemen HM, Porte RJ: Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: a pooled analysis. Gastrointest Endosc 2005;62:383–389.
45.
Leung KK, Ross WA, Evans D, et al: Pancreatic cystic neoplasm: the role of cyst morphology, cyst fluid analysis, and expectant management. Ann Surg Oncol 2009;16:2818–2824.
46.
Raval JS, Zeh HJ, Moser AJ, et al: Pancreatic lymphoepithelial cysts express CEA and can contain mucous cells: potential pitfalls in the preoperative diagnosis. Mod Pathol 2010;23:1467–1476.
47.
Khalid A, McGrath KM, Zahid M, et al: The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. Clin Gastroenterol Hepatol 2005;3:967–973.
48.
Khalid A, Zahid M, Finkelstein SD, et al: Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest Endosc 2009;69:1095–1102.
49.
Shen J, Brugge WR, Dimaio CJ, Pitman MB: Molecular analysis of pancreatic cyst fluid: a comparative analysis with current practice of diagnosis. Cancer Cytopathol 2009;117:217–227.
50.
Sawhney MS, Devarajan S, O’Farrel P, et al: Comparison of carcinoembryonic antigen and molecular analysis in pancreatic cyst fluid. Gastrointest Endosc 2009;69:1106–1110.
51.
Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature 2005;435:834–838.
52.
Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K: The microRNA spectrum in 12 body fluids. Clin Chem 2010;56:1733–1741.
53.
Szafranska AE, Doleshal M, Edmunds HS, et al: Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem 2008;54:1716–1724.
54.
Cho WC: OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 2007;6:60.
55.
Schonleben F, Qiu W, Ciau NT, et al: PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res 2006;12:3851–3855.
56.
Sato N, Rosty C, Jansen M, et al: STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol 2001;159:2017–2022.
57.
Iacobuzio-Donahue CA, Klimstra DS, Adsay NV, et al: Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol 2000;157:755–761.
58.
Iacobuzio-Donahue CA, Wilentz RE, Argani P, et al: Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression. Am J Surg Pathol 2000;24:1544–1548.
© 2011 S. Karger AG, Basel and IAP
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
